Share on StockTwits

Synergy Pharmaceuticals (NASDAQ:SGYP) SVP Bernard Denoyer acquired 2,500 shares of the company’s stock in a transaction dated Friday, May 23rd. The shares were purchased at an average cost of $3.89 per share, for a total transaction of $9,725.00. Following the acquisition, the senior vice president now directly owns 12,952 shares of the company’s stock, valued at approximately $50,383. The transaction was disclosed in a filing with the SEC, which is available at this link.

Shares of Synergy Pharmaceuticals (NASDAQ:SGYP) opened at 4.42 on Friday. Synergy Pharmaceuticals has a 52 week low of $3.39 and a 52 week high of $6.70. The stock’s 50-day moving average is $4.20 and its 200-day moving average is $4.9. The company’s market cap is $414.1 million.

Synergy Pharmaceuticals (NASDAQ:SGYP) last announced its earnings results on Tuesday, May 13th. The company reported ($0.18) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.23) by $0.05. On average, analysts predict that Synergy Pharmaceuticals will post $-0.86 earnings per share for the current fiscal year.

Separately, analysts at Aegis raised their price target on shares of Synergy Pharmaceuticals to $28.00 in a research note on Monday, March 24th. Four analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average price target of $16.33.

Synergy Pharmaceuticals, Inc is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (NASDAQ:SGYP), disorders and diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.